Perrigo announced that the Food and Drug Administration (FDA)’s final approval for Nystatin and Triamcinolone Acetonide Cream USP, the generic version of Mycolog II Cream. 

Mycolog II Cream, a synthetic corticosteroid combined with a polyene antifungal, is indicated to treat cutaneous candidiasis. Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. Triamcinolone acetonide is mainly effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions. 

Related Articles

Nystatin and Triamcinolone Acetonide Cream USP will be available as a 100,000 units/g and 1mg/g strength. It is anticipated to launch in the 4th quarter of 2017.

For more information call (866) 634-9120 or visit Perrigo.com.